Type 2 diabetes mellitus as risk factor for colorectal cancer
- PMID: 18465362
- DOI: 10.1080/13813450802008455
Type 2 diabetes mellitus as risk factor for colorectal cancer
Abstract
Colorectal cancer occurs more frequently in patients with type 2 diabetes mellitus. The hyperinsulinemia-hypothesis suggests that elevated levels of insulin and free IGF-1 promote proliferation of colon cells and lead to a survival benefit of transformed cells, ultimately resulting in colorectal cancer. In patients with type 2 diabetes mellitus, epidemiological studies show an increased risk for colorectal cancer and an even higher risk if patients are treated with sulphonylureas or insulin. Moreover, tumour progression at hyperinsulinemia is more rapid and tumour-associated mortality is increased. Colorectal cancer can be avoided by screening. Recommendations for colorectal cancer screening should employ the recent epidemiologic evidence. All patients with type 2 diabetes mellitus should be recommended to undergo colonoscopy before starting insulin therapy, and screening intervals should not exceed 5 years. For this concept, a review of the evidence is presented, and a screening algorithm for colorectal cancer in patients with type 2 diabetes mellitus is proposed.
Similar articles
-
[Colorectal carcinoma screening in patients with type 2 diabetes mellitus].Z Gastroenterol. 2006 Nov;44(11):1153-65. doi: 10.1055/s-2006-927132. Z Gastroenterol. 2006. PMID: 17115358 Review. German.
-
Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea.Dis Colon Rectum. 2008 May;51(5):593-7. doi: 10.1007/s10350-007-9184-1. Epub 2008 Jan 25. Dis Colon Rectum. 2008. PMID: 18219529
-
Diabetes and the risk for colorectal cancer.J Diabetes Complications. 2012 Jan-Feb;26(1):50-5. doi: 10.1016/j.jdiacomp.2011.11.003. Epub 2012 Feb 7. J Diabetes Complications. 2012. PMID: 22321219 Review.
-
Type 2 diabetes and cancer: what is the connection?Mt Sinai J Med. 2010 Mar-Apr;77(2):197-213. doi: 10.1002/msj.20167. Mt Sinai J Med. 2010. PMID: 20309918 Review.
-
Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms.World J Gastroenterol. 2011 Jan 28;17(4):444-8. doi: 10.3748/wjg.v17.i4.444. World J Gastroenterol. 2011. PMID: 21274373 Free PMC article. Review.
Cited by
-
Colon Cancer and Obesity: A Narrative Review.Cureus. 2022 Aug 1;14(8):e27589. doi: 10.7759/cureus.27589. eCollection 2022 Aug. Cureus. 2022. PMID: 36059323 Free PMC article. Review.
-
Prognostic Impact of Type 2 Diabetes in Metastatic Colorectal Cancer.Cureus. 2023 Jan 18;15(1):e33916. doi: 10.7759/cureus.33916. eCollection 2023 Jan. Cureus. 2023. PMID: 36819384 Free PMC article.
-
Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II Diabetes Mellitus and Colorectal Cancer.J Glob Oncol. 2018 Jul;4:1-10. doi: 10.1200/JGO.18.00018. J Glob Oncol. 2018. PMID: 30084749 Free PMC article.
-
Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice.Horm Cancer. 2010 Dec;1(6):320-30. doi: 10.1007/s12672-010-0020-z. Horm Cancer. 2010. PMID: 21761363 Free PMC article.
-
The impact of metformin on survival in diabetes patients with operable colorectal cancer: A nationwide retrospective cohort study.J Int Med Res. 2023 Apr;51(4):3000605231168033. doi: 10.1177/03000605231168033. J Int Med Res. 2023. PMID: 37077173 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous